BCDA · BioCardia, Inc.

BioCardia, Inc. announced a significant regulatory milestone through its formal clinical consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) on April 20, 2026. The PMDA's determination that existing clinical safety and efficacy data from US trials for the CardiAMP® Cell Therapy in ischemic heart failure is likely sufficient to support market clearance represents a critical step toward commercialization in Japan, a major global market. Alignment was reached across key areas including the acceptability of foreign US data, specific indications for patient use, the strategic approach for therapy introduction, and requirements for post-marketing studies, reducing regulatory uncertainty. The company will receive formal minutes from PMDA to outline next steps and timelines for a potential filing, positioning BioCardia closer to approval. CEO Dr. Peter Altman highlighted unanimous support from expert cardiologists and reaffirmed the trajectory for CardiAMP to become Japan's first approved minimally invasive biologic therapy for this indication. CardiAMP, granted FDA Breakthrough designation, employs autologous bone marrow cells delivered via catheter to enhance capillary density and mitigate myocardial fibrosis, addressing microvascular dysfunction in heart failure patients. This development underscores BioCardia's progress in its cardiac clinical-stage pipeline, supported by funding from the Maryland Stem Cell Research Fund and CMS reimbursement, enhancing its global leadership in cellular therapeutics for cardiovascular diseases.